ImmunXperts offers services to support your drug development process, be it by mitigating risks through immunogenicity assessment or by saving time and money through custom assay development.
In collaboration with our scientific advisors and international partners, ImmunXperts offers access to a unique team of seasoned immunology experts. ImmunXperts provides a comprehensive package, allowing you to outsource the full immunology assessment, or to cherry-pick the solutions or technologies needed/that fit your exact requirements.
We offer great flexibility in dealing with your specific demands and changing priorities. Our creative mind-set, our strong and interactive relationship with our customers and our long term experience in the field make us a reliable partner to meet your specific needs.
The key process in T cell dependent antibody production is peptide presentation by antigen presenting cells to T cells, in combination with co-stimulatory signals and cytokine secretion. These three signals will stimulate the T cells to proliferate and differentiate, in order to be able to help the B cells to produce antibodies towards the antigen. Antibodies produced towards the administered drug (anti-drug antibodies or ADAs) are the main clinical immunogenicity problem. These ADAs can lead to a decreased or enhanced clearance of the drug, or can have no effect at all. If the drug mimics an endogenous counterpart, the ADAs might also bind the endogenous protein, which can lead to severe consequences for the patients’ health. The process from antigen presentation until ADA production cannot (yet) be tested in vitro. Therefore, T cell proliferation is can be used as a surrogate marker to measure the immunogenic potential of a drug candidate in development.
T cell activation assays have a long tradition in vaccine testing (wanted immunogenicity), but are also employed to asses possible unwanted immunogenicity induced by therapeutic proteins.
ImmunXperts offers several types of T cell activation assays:
ImmunXperts has experience with several readout formats:
ImmunXperts offers a comprehensive package of tools and services to measure immunogenicity during pre-clinical and clinical studies.
Recent advances in the field of Immuno-oncology have shown great promise in the treatment of a wide variety of malignancies. Several strategies involving monoclonal antibodies (or other biologics platforms), cytokines, small molecule compounds or cellular therapies have been applied to modulate the immune system.
Early evaluation and screening of the immunomodulatory effectiveness of candidate therapeutics using In Vitro bioassays is a critical step in the development of novel or combination immunotherapies.
ImmunXperts has extensive experience with In Vitro assays using human primary immune cells which can be implemented in the field of immuno-oncology, for instance:
ImmunXperts has a unique knowledge in building custom assays that can be useful to cell therapy companies
Cell Therapy products offer the potential of curing diseases that today have only palliative treatments in the best case.
The ability to produce large quantities of biological products with predictable quality and quantifiable potency is becoming critical. And this is also a regulatory requirement for phase III and commercialization.
ImmunXperts has the capacity to develop custom in vitro assays to screen immunomodulatory properties of Stem Cells, selecting the potency markers that make the most sense for each product.
Functional & Cell Type Specific Assays Services
Protein Purification and Quantification Services
Biochemistry & Molecular Biology Services
ImmunXperts offers access to In Silico tools for immune profiling and lead optimization. In Silico tools are fast, sequence based and low cost, and thus are perfectly suited for assessing large numbers of lead candidates in an early development phase.
These tools can be used for:
ImmunXperts SA has not received any reviews.
ImmunXperts SA has not received any endorsements.